Horse tranquilliser trial is awarded $750,000 grant for Parkinson’s research

News

Author: Simge Eva DoganPublished: 26 July 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

ketamine

Researchers at the University of Arizona College of Medicine, Tucson, US, will be trialling ketamine – a recreational drug previously used to medicate people with depression – as a treatment for Parkinson’s.

The research – led by Dr Scott Sherman – is being supported with a three-year grant of $750,000 from the Arizona Biomedical Research Commission.

The initial clinical trial will test the effect of ketamine for treating dyskinesia in 10 patients. In addition, the researchers will carry out a separate rodent study to examine how the drug affects the brain.

Dr Scott Sherman, a neurologist at the University of Arizona College of Medicine, said: “Ketamine has been long overlooked. Now it could prove very useful for Parkinson’s patients.”

For information on the latest Parkinson’s research please visit the European Parkinson’s Disease Association website.

For more information on this article click here.

Go Back

Share this story

Comments


Related articles


A composite image of Cathy Molohan and Keyoumars Ashkan.

sponsored article

Episodes

Podcast: Deciding to have DBS surgery

Two guests discuss deep brain stimulation for Parkinson’s disease

READ MORE
Man with fatigue

Resources & Tools

Is your Parkinson’s making you tired?

Register for this free, hour-long webinar

READ MORE
walked

Interviews

The man who walked 80km in one day for Parkinson’s

Clint Bauld walked for 24 hours in aid of Parkinson’s

READ MORE